CHIP-CC Registry: A Prospective Multicenter Registry of Complex High-Risk PCI in China

Complex high-risk indicated patients undergoing percutaneous coronary intervention represent a clinically challenging population. These patients often have complex coronary anatomy, impaired cardiac function, hemodynamic vulnerability, advanced age, frailty, or multiple comorbidities. Although advances in interventional techniques, adjunctive devices, intravascular imaging, physiological assessment, and mechanical circulatory support have expanded the feasibility of PCI in this population, evidence regarding optimal treatment strategies and long-term outcomes remains limited, particularly in real-world Chinese practice.

This study is a prospective, multicenter, observational registry conducted in tertiary hospitals with experience in complex high-risk PCI. The study will enroll approximately 1,000 patients who meet the predefined eligibility criteria and undergo PCI as part of routine clinical care. No additional interventional treatment will be mandated by the protocol. PCI strategy, use of intravascular imaging such as IVUS or OCT, physiological assessment such as FFR or QFR, lesion preparation techniques, complete or incomplete revascularization, staged PCI, antithrombotic therapy, and the use and type of mechanical circulatory support will be determined by the treating physicians according to contemporary guidelines, expert consensus, and local clinical practice.

Eligible patients include adults aged 18 to 90 years who are considered by the heart team to have an indication for coronary revascularization but are at high risk for coronary artery bypass grafting or decline CABG, and for whom PCI is considered beneficial. Patients are required to have left ventricular ejection fraction ≤35%, or left ventricular ejection fraction ≤40% with severe mitral regurgitation, together with complex PCI features such as unprotected left main disease, last remaining patent coronary artery PCI, three-vessel disease, heavily calcified lesions requiring rotational atherectomy, or chronic total occlusion requiring bilateral angiography or retrograde techniques. Patients with acute ST-segment elevation myocardial infarction within 1 week, cardiogenic shock, inability to complete follow-up, or other conditions considered unsuitable by investigators will be excluded.

Data collection will include demographic characteristics, medical history, comorbidities, medication use, cardiac function, physical examination, laboratory tests, electrocardiography, echocardiography, quality-of-life assessments, coronary angiography, lesion characteristics, procedural details, use of intravascular imaging or physiological assessment, lesion preparation, mechanical circulatory support, procedural success, completeness of revascularization, residual SYNTAX score, and peri-procedural complications. Follow-up will be performed at 1 month, 3 months, 6 months, 1 year, and 2 years after PCI by outpatient visit or telephone contact. Quality-of-life assessments will be collected at 3 months, 6 months, 1 year, and 2 years. Clinical events suggestive of cardiovascular outcomes, including chest pain, myocardial infarction, heart failure, or other cardiovascular hospitalization, will be recorded and adjudicated according to predefined endpoint definitions.

The primary endpoint is all-cause mortality at 1 year after PCI. Secondary endpoints include 1-year major adverse cardiovascular events, defined as a composite of all-cause death, myocardial infarction, target vessel revascularization, and heart failure hospitalization; cardiac death; myocardial infarction; target vessel revascularization; heart failure hospitalization; major bleeding defined as BARC type 3 or 5 bleeding; and quality-of-life scores. Additional analyses will evaluate the association between clinical, anatomical, procedural, imaging, physiological, and mechanical circulatory support variables and clinical outcomes. The registry will also be used to develop a risk prediction model to support clinical decision-making in patients undergoing CHIP-PCI.

This registry is expected to provide real-world evidence on contemporary CHIP-PCI practice in China, including patient characteristics, procedural strategies, use of adjunctive technologies, short- and long-term outcomes, and predictors of adverse events. The findings may help optimize risk stratification, procedural planning, and post-PCI management in complex high-risk patients.

• Major Adverse Cardiovascular Events at 1 Year After PCI [Time frame: 1 year after PCI]
• Cardiac death at 1 year after PCI [Time frame: 1 year after PCI]
• Myocardial Infarction at 1 Year After PCI [Time frame: 1 year after PCI]
• Target Vessel Revascularization at 1 Year After PCI [Time frame: 1 year after PCI]
• Hospitalization for Heart Failure at 1 Year After PCI [Time frame: 1 year after PCI]
• Major Bleeding at 1 Year After PCI [Time frame: 1 year after PCI]
• Change in Health-Related Quality of Life Assessed by EQ-5D-5L [Time frame: Baseline, 3 months, 6 months, 1 year, and 2 years after PCI]
• Change in Angina-Related Quality of Life Assessed by the Seattle Angina Questionnaire [Time frame: Baseline, 3 months, 6 months, 1 year, and 2 years after PCI]